{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:06:19Z","timestamp":1788793579176,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jcf.2025.04.012","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T15:55:51Z","timestamp":1747324551000},"page":"716-723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["LONGITUDE: An observational study of the long-term effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people aged \u226512 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Gabriela","family":"Vega-Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-3424","authenticated-orcid":false,"given":"Gordon","family":"MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wilfin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciar\u00e1n","family":"Haugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl A.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"W\u00f6hling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2805-930X","authenticated-orcid":false,"given":"Sarah L.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Charman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0580-2478","authenticated-orcid":false,"given":"Siobh\u00e1n B.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9678","key":"10.1016\/j.jcf.2025.04.012_bib0001","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.04.012_bib0002","unstructured":"Cystic Fibrosis Trust. UK cystic fibrosis registry 2022 annual data report. 2023."},{"issue":"1","key":"10.1016\/j.jcf.2025.04.012_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"17","key":"10.1016\/j.jcf.2025.04.012_bib0004","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"44","key":"10.1016\/j.jcf.2025.04.012_bib0005","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2025.04.012_bib0006","series-title":"30th Annual North American Cystic Fibrosis Conference","author":"Van Goor","year":"2016"},{"issue":"7","key":"10.1016\/j.jcf.2025.04.012_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cells11071243","article-title":"CFTR modulator therapies: potential impact on airway infections in cystic fibrosis","volume":"11","author":"Saluzzo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jcf.2025.04.012_bib0008","unstructured":"European Medicines Agency. Kaftrio summary of product characteristics. 2023."},{"issue":"1","key":"10.1016\/j.jcf.2025.04.012_bib0009","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of Elexacaftor\/Tezacaftor\/Ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del Allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2025.04.012_bib0010","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.012_bib0011","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jcf.2025.04.012_bib0012","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S1569-1993(24)00306-0","article-title":"EPS10.08 LONGITUDE: an observational study of the long-term effectiveness of ELX\/TEZ\/IVA in people with CF using data from the UK CF Registry \u2014 Preliminary results from the subgroup aged 6\u201311 years","volume":"23","author":"Vega-Hernandez","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2025.04.012_bib0013","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for Cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2025.04.012_bib0014","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2025.04.012_bib0015","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.04.012_bib0016","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis and at least one <em>F508del<\/em>Allele: 144-week interim results from a 192-week open-label extension study","author":"Daines","year":"2023","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1016\/j.jcf.2025.04.012_bib0017","first-page":"381","article-title":"Safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del Alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jcf.2025.04.012_bib0018","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.04.012_bib0019","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jcf.2020.04.008","article-title":"Average rate of lung function decline in adults with cystic fibrosis in the United Kingdom: data from the UK CF registry","volume":"20","author":"Caley","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.012_bib0020","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1569-1993(19)30360-1","article-title":"P066 Disease progression and burden in patients with cystic fibrosis homozygous for F508del across Europe in an observational registry (VOICE Study)","volume":"18","author":"McKone","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.04.012_bib0021","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chest.2020.09.084","article-title":"Pulmonary exacerbations in adults with Cystic Fibrosis: a grown-up issue in a changing cystic fibrosis landscape","volume":"159","author":"Stanford","year":"2021","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jcf.2025.04.012_bib0022","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","article-title":"Lung infections associated with cystic fibrosis","volume":"15","author":"Lyczak","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jcf.2025.04.012_bib0023","series-title":"UK cystic fibrosis registry 2021 annual data report","year":"2022"},{"key":"10.1016\/j.jcf.2025.04.012_bib0024","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fped.2018.00403","article-title":"Respiratory bacterial culture sampling in expectorating and non-expectorating patients with Cystic fibrosis","volume":"6","author":"Eyns","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jcf.2025.04.012_bib0025","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s41030-023-00241-z","article-title":"Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on healthcare resource utilization and associated costs among people with Cystic Fibrosis in the US: a retrospective claims analysis","volume":"9","author":"Schechter","year":"2023","journal-title":"Pulm Ther"},{"key":"10.1016\/j.jcf.2025.04.012_bib0026","series-title":"2022 Annual data report","year":"2023"},{"issue":"5","key":"10.1016\/j.jcf.2025.04.012_bib0027","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/ppul.25250","article-title":"Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic","volume":"56","author":"Patel","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"10.1016\/j.jcf.2025.04.012_bib0028","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2025.04.012_bib0029","first-page":"281","article-title":"CFTR modulators: transformative therapies for cystic fibrosis","volume":"27","author":"Dwight","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jcf.2025.04.012_bib0030","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(21)01602-7","article-title":"177: impact of elexacaftor\/tezacaftor\/ivacaftor therapy use on pulmonary exacerbation rates during the COVID-19 pandemic","volume":"20","author":"Menten","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:14:48Z","timestamp":1778822088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325014675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1569199325014675"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.04.012","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LONGITUDE: An observational study of the long-term effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people aged \u226512 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Vertex Pharmaceuticals Incorporated. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}